An undertaking that involved combining massive amounts of graphics processing power could provide key leverage for researchers looking to develop potential cures and treatments for the novel coronavirus behind the current global pandemic. Immunotherapy startup ImmunityBio is working with Microsoft’s Azure to deliver a combined 24 petaflops of GPU computing capability for the purposes of modelling, in a very high degree of detail, the structure o the so-called “spike protein” that allows the SARS-CoV-2 virus that causes COVID-19 to enter human cells.
This new partnership means that they were able to produce a model of the spike protein within just days, instead of the months it would’ve taken previously. That time savings means that the model can get in the virtual hands of researchers and scientists working on potential vaccines and treatments even faster, and that they’ll be able to gear their work towards a detailed replication of the very protein they’re trying to prevent from attaching to the human ACE-2 proteins’ receptor, which is what sets up the viral infection process to begin with.
The main way that scientists working on treatments look to prevent or minimize the spread of the virus within the body is to block the attachment of the virus to these proteins, and the simplest way to do that is to ensure that the spike protein can’t connect with the receptor it targets. Naturally-occurring antibodies in patients who have recovered from the novel coronavirus do exactly that, and the vaccines under development are focused on doing the same thing pre-emptively, while many treatments are looking at lessening the ability of the virus to latch on to new cells as it replicates within the body.
In practical terms, the partnership between the two companies included a complement of 1,250 NVIDIA V100 Tensor Core GPUs designed for use in machine learning applications from a Microsoft Azure cluster, working with ImmunityBio’s existing 320 GPU cluster that is tuned specifically to molecular modeling work. The results of the collaboration will now be made available to researchers working on COVID-19 mitigation and prevention therapies, in the hopes that they will enable them to work more quickly and effectively towards a solution.
